Every 424B that Humacyte, Inc. (HUMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HUMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMA filings page.
Humacyte, Inc. is offering 47,619,048 shares of its common stock pursuant to this prospectus supplement, at a public offering price of $1.05 per share (underwriters have a 30‑day option to purchase an additional 7,142,857 shares). The offering's gross proceeds are stated as $50,000,000.40, with estimated net proceeds to the company of approximately $47.0 million before expenses (approximately $53.85 million if the underwriters fully exercise their option).
The company reports that shares outstanding after the offering would be 269,638,156 (or 276,781,013 if the option is fully exercised). The prospectus supplement also discloses recently announced positive top-line interim results from the V012 Phase 3 trial, meeting its primary endpoint, and states an intention to submit a supplemental BLA in the second half of 2026. The company notes substantial doubt about its ability to continue as a going concern absent additional financing.
Humacyte, Inc. filed a preliminary prospectus supplement to offer shares of common stock (number and price not specified in the excerpt) and granted underwriters a 30-day option to purchase additional shares. Net proceeds are intended to fund Symvess commercialization, a planned supplemental BLA filing for hemodialysis, pipeline development and working capital.
The supplement also discloses positive top-line interim results from the V012 Phase 3 trial: ATEV patients averaged 220 catheter-free days versus 129 for AV fistula (p=0.00070), with infection rates of 6 vs. 23 per 100 patient-years. The company plans a supplemental BLA submission in the second half of 2026. Management reports available cash and equity capacity that fund operations into the first quarter of 2027 but states there is substantial doubt about its ability to continue as a going concern without additional financing.
Humacyte, Inc. is offering 25,000,000 shares of common stock at $0.80 per share pursuant to this prospectus supplement, representing a gross offering size of $20,000,000. Delivery is expected on or about March 20, 2026.
The placement agent fee reduces estimated net proceeds to approximately $18,400,000, which the company intends to use to fund commercialization of Symvess in the vascular trauma indication, support a planned BLA supplement and Phase 3 readout activities, advance pipeline programs, and for working capital and general corporate purposes. The company discloses substantial doubt about its ability to continue as a going concern and estimates cash runway into the first quarter of 2027 absent additional financing.
Humacyte, Inc. plans to sell up to $60,000,000 of common stock through an at‑the‑market program with TD Securities (USA) LLC (TD Cowen), which will act as sales agent on Nasdaq and other trading markets. Humacyte will compensate TD Cowen with a commission of up to 3% of the gross sales price on any shares sold.
The company expects to use any net proceeds to fund commercialization of its FDA‑approved Symvess product for the vascular trauma indication, advance additional bioengineered tissue product candidates, and for working capital and general corporate purposes. Humacyte reports 158,835,303 shares of common stock outstanding as of September 30, 2025, and illustrates issuance of additional shares under the program, which would dilute existing holders. The broader shelf registration explains that, because existing cash and an equity facility will not fund operations for more than one year beyond the relevant filing date without new capital, there is substantial doubt about the company’s ability to continue as a going concern, underscoring the importance of external financing like this offering.